DICAM-specific antibodies and uses thereof
US10428144B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Dec 17, 2015 |
| Grant date | Oct 1, 2019 |
| Priority date | — |
| Expiry date | Jan 26, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/76
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Novel antibodies directed against Dual Ig domain containing cell adhesion molecule (DICAM) are described. These anti-DICAM antibodies are capable of detecting DICAM by Western blot and/or flow cytometry, blocking the interaction between DICAM and its ligand αVβ3 integrin, and/or blocking the migration of inflammatory cytokine-secreting TH17 lymphocytes across the blood brain barrier. Uses of these antibodies or compositions comprising same for the diagnosis, prevention and/or treatment of autoimmune/inflammatory conditions, such as neuroinflammatory conditions, and for the targeting, identification and selection of inflammatory cytokine-secreting TH17 lymphocytes or precursor thereof are also disclosed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.